Navigation Links
Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
Date:2/19/2009

2008 (2007: $nil) and upfront payments in respect of in-licensed technology of $75.0 million in 2007 (2008: $nil), cash inflow from operating activities for the three months to December 31, 2008 increased by $280.6 million compared to the same period in 2007.

2. Product sales

    For the year to December 31, 2008 product sales increased by 27% to
$2,754.2 million (2007: $2,170.2 million) and represented 91% of total
revenues (2007: 89%).
    Product Highlights

                                                     US Rx       US Average
                              Sales     Sales     Growth (1)    Annual Market
    Product                    $M     Growth (2)      (2)         Share(1)
    Specialty
    Pharmaceuticals
    ADDERALL XR              1,101.7        +7%         -5%           22.6%
    VYVANSE                    318.9      +317%       +388%            8.2%
    DAYTRANA                    78.7       +23%        -11%            1.8%
    LIALDA / MEZAVANT          140.4      +178%       +204%           11.7%
    PENTASA                    185.5        +5%         -1%           16.7%
    FOSRENOL                   155.4       +52%         -4%            8.1%
    XAGRID                      78.7       +18%        n/a             n/a

    Human Genetic Therapies
    ELAPRASE                   305.1       +68%        n/a(3)          n/a(3)
    REPLAGAL                   176.1       +22%        n/a(4)          n/a(4)
    FIRAZYR                      0.5        n/a        n/a(4)          n/a(4)

    (1) Product specific prescription data is provided by IMS Health
        ("IMS"), a leading global provider of business intelligence for the
        pharmaceutical and healthcare industries. All other US market share
        data stated in the text below is also provided by IMS.
    (2) Compared to 2007
    (3) IMS data not available
    (4) Not sold in the US


    Specialty Pharmaceuticals
    US ADHD mar
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 

Related biology technology :

1. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
2. Shire plc: Change to Directors Details
3. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
4. Shires New Product Portfolio Delivers Strong Quarterly Performance
5. Change of Name to Shire plc
6. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
7. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
8. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
9. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
10. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
11. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Del. and CHARLOTTESVILLE, Va., Dec. 15 /PRNewswire-FirstCall/ ... and the University of Virginia (UVa) in ... into a strategic research collaboration to enhance ... artery disease (CAD) with a secondary focus ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The collaborative ...
(Date:12/15/2009)... The Center for Business Intelligence (CBI), a ... announce the full agenda for the ... . The forum will take place at ... ,, Over 1,500 senior-level Finance, Accounting, Audit ... event since its inception, and this year,s ...
(Date:12/15/2009)... Prinz Law Office has announced the launch of several ... secure legal services in the current economic climate. ... the opportunity to finance legal services over a period ... any equity in their start-up companies. The second ... fixed montly payment arrangements over 6 to 12 month ...
(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
Breaking Biology Technology:AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4
... With the FDA for the Fourth Genmab Antibody ... Company,s Collaboration with Roche., COPENHAGEN, December 12 ... Drug application (IND) for a,Genmab antibody developed under the ... by Roche. Genentech and Roche are collaborating on,development of ...
... EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today,announced that the independent Data ... Company,s on-going MAESTRO-03 U.S. pivotal phase III,clinical trial ... MS and,recommended that the trial continue., This ...
... Lucid, Inc., (http://www.lucid-tech.com ), a leading U.S. ... Stahel as Director, Asia Pacific Region., Based ... newly created,position based on his extensive medical technology ... in the development of medical,technology and pre-cancer and ...
Other Biology Technology:Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region 2
(Date:12/16/2009)... rituals can help them get psyched up for contests, ... which many athletes gobble down before and during events, ... "These agents are treatments for the symptoms of an ... research at Indiana University focuses on musculoskeletal health and ... or train at a certain level, but pain occurs ...
(Date:12/16/2009)... 1 iQor, a global provider of business ... InfoWorld 100 Awards Top 100 IT project ... was the first submission for iQor. ,, "We are ... companies," said Vikas Kapoor, president and CEO of iQor. ... allowing us to work faster, smarter and with the ...
(Date:12/16/2009)... IgeaCare Solutions Inc. is pleased to ... healthcare communications company previously operating as IgeaCare Systems ... move forward under new leadership and funding. ,, ... to the position of Chief Executive Officer. Under ... providing a superior servicing and support model; fast ...
Breaking Biology News(10 mins):NSAIDs: Take 'em early and often when competing? Think again 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2New IVF Software MedITEX to be Presented at the ESHRE Exhibition 12663 1New IVF Software MedITEX to be Presented at the ESHRE Exhibition 12663 2Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 1Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 2Oclaro 28TM 29 Hits Milestone With Clarity 28TM 29 Fluorescence Filters 12662 3Inoperable Colon Cancer Responds to New Treatment 49145 1Inoperable Colon Cancer Responds to New Treatment 49145 2
... University of Missouri suggests that eating a certain form ... the prostate cancer-fighting potential of the tomato. The positive ... studies, but, until now, researchers did not know exactly ... greatest protective effect from tomatoes comes from rehydrating tomato ...
... core, why are there magnetic anomalies in rocks, how ... grow? These and many other important questions the mineral ... EuroMinScI (European Mineral Sciences Initiative) Conference held in Giens, ... event of the EuroMinScI Community, providing a venue for ...
... 29th May, a report setting out a "comprehensive and ... presented by the report,s author Mr. Pavan Sukhdev. The ... of Germany and Stavros Dimas the Commissioner responsible for ... understanding of the true economic value of the benefits ...
Other Biology News:Young mineral scientists rock! 2Young mineral scientists rock! 3Young mineral scientists rock! 4The Economics of Ecosystems and Biodiversity- TEEB 2The Economics of Ecosystems and Biodiversity- TEEB 3The Economics of Ecosystems and Biodiversity- TEEB 4The Economics of Ecosystems and Biodiversity- TEEB 5